Within the biological spectrum of breast cancers, those displaying gene amplification of human epidermal growth factor receptor 2 (HER2 +) and those that are triple-negative (TN, i.e., negative for ER, PR and HER2) are generally considered biologically aggressive tumor subtypes. The gene discussed is ERBB2; the disease is breast carcinoma.